Skip to main content
. 2020 Feb;62(2):178–190. doi: 10.1165/rcmb.2018-0147OC

Figure 1.

Figure 1.

Both oropharyngeal bleomycin (OP-bleo) and subcutaneous bleomycin (SC-bleo) induce comparable pulmonary fibrosis with upregulating P-gp (permeability glycoprotein) and BCRP (breast cancer resistance protein) gene expression. (A) Percent initial body weight. Initial average body weight was 26 ± 2 g for each group. (B) Wet weight of the left lung was recorded after OP-bleo or SC-bleo. (C) Hydroxyproline (Hyp) content of the left lung was measured via liquid chromatography–tandem mass spectrometry (LC-MS/MS) after OP-bleo or SC-bleo. (D) Gene expression profiling of fibrosis markers. (E) Pressure–volume curve, (F) tissue elasticity, (G) tissue damping, as a measure of lung function obtained by flexiVent. Gene expression of drug efflux–associated ATP-binding cassette (ABC) transporters after (H) OP-bleo or (I) SC-bleo. n = 5 mice per group for control and 6 mice per OP-bleo group, and 5 mice per SC-bleo group. *P < 0.05 indicates significant difference from control group. PVP = pressure–volume curve.